Nuvectis Pharma (NVCT) Net Cash Flow (2021 - 2026)

Nuvectis Pharma has disclosed Net Cash Flow across 6 years of filings, most recently posting -$6.5 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$6.5 million, down 157.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.7 million (down 145.52% YoY), and the FY2025 annual result was $13.1 million, up 2309.27% from the prior year.
• Net Cash Flow came in at -$6.5 million for Q1 2026 at Nuvectis Pharma, down from -$3.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $11.3 million in Q1 2025 to a low of -$6.5 million in Q1 2026.
• The 5-year median for Net Cash Flow is -$1.3 million (2024), against an average of $1.1 million.
• Peak annual rise in Net Cash Flow reached 3252.37% in 2025, while the deepest fall reached 379.18% in 2025.
• Nuvectis Pharma's Net Cash Flow stood at -$3.6 million in 2022, then gained by 19.58% to -$2.9 million in 2023, then jumped by 146.51% to $1.4 million in 2024, then plunged by 379.18% to -$3.8 million in 2025, then tumbled by 70.8% to -$6.5 million in 2026.
• The last three Net Cash Flow figures came in at -$6.5 million (Q1 2026), -$3.8 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.